What's new?

• Sofinnova Crossover Fund 1 is the largest healthcare crossover fund focused on Europe.
• With this new fund, Sofinnova Partners actively pursues the strategy to broaden its Life Sciences platform to invest across the value chain, from seed stage to late-stage companies.
• Bpifrance* and CNP Assurances acted as sponsors for the fund.

Paris, France – April 4th, 2018 — Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced today the launch of Sofinnova Crossover I with €275 million ($340 million), above the original first close target of €250 million. With this new fund, Sofinnova Partners goes one step further in the execution of its growth plan, aimed at expanding its coverage across the Life Sciences space with dedicated sector teams.

Pursuing a strategy Sofinnova Partners has successfully applied for decades with its early-stage focused Capital Funds, Sofinnova Crossover I will invest in the biopharmaceutical and medical device sectors. The fund will focus primarily on therapeutic and game-changing companies driven by experienced management. As a lead or cornerstone investor, the fund will seek to invest in about 15 late stage private and public companies. About 80% of the investments will be made in European companies, with the remaining 20% outside of Europe primarily in North America. A dedicated, highly experienced team of four partners will invest Sofinnova Crossover I, leveraging on Sofinnova Partners’ wider experience, track record and organizational support. This new fund attracted premier international investors, predominantly sovereign funds, insurance companies, corporations and family offices. Commitments came from Europe, including France, Italy, Denmark, Ireland, and Switzerland but also from Asian investors in China and Singapore. In addition to Bpifrance* and CNP Assurances, investors include a major Chinese biopharmaceutical company, the Danish State Investment fund, and family offices like Fidim or KCK representing leading industrial families in Europe and Asia.

Antoine Papiernik, Chairman of Sofinnova Partners, said, “With the launch of this new crossover activity, Sofinnova builds upon its unique early stage track record. Many of the companies we initially funded have become over the years large, billion-euro companies, and we have gained invaluable experience in helping them to the next level. This fund will complete our investment platform across the life-sciences value-chain, allowing us to fund companies from the seed stage to the late-stage.”

Jacques Theurillat, Partner in the crossover team at Sofinnova Partners, added: “The European healthcare market has matured with hundreds of late stage private and public companies looking for growth capital, and Sofinnova Partners, with its name, track record and experience, is particularly well positioned to identify the best European deals and transform them into global leaders.”

Triago acted as placement agent and Clifford Chance Europe LLP acted as legal counsel on Sofinnova Crossover I.

* Bpifrance directly and with the “Investment for the Future” Program, managed by the SGPI and operated by Bpifrance

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead investor in start-ups and corporate spin-offs and has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management.




Diatos SA, a privately held biopharmaceutical company that develops novel therapeutics based on its innovative drug-targeting (TSP) and intracellular-delivery (DPV) technologies, announced today the appointments of Denis Ravel, Ph.D., to the position of Chief R&D Officer, and Sandrine Leonardi to the position of Finance Director. With these appointments Diatos has completed its core management team.

Dr. Ravel brings 18 years of experience in the biotechnology and pharmaceutical industry with extensive background in preclinical and early clinical development of new drugs in the field of metabolic diseases. Prior to joining Diatos, Dr. Ravel was Director of Pharmaceutical Development at Genset and in charge of the Genset San Diego Research Center. In his position at Genset, he led the preclinical development of Famoxin [APM-1], a recombinant protein with anti-diabetic activities. Prior to joining Genset in 2001, Dr Ravel worked for 16 years at Servier, as Senior Pharmacologist and as Project Manager of preclinical and early clinical Drug Development before being promoted to Head of Department. Dr. Ravel obtained a Ph.D. in Biochemistry from Université Pierre et Marie Curie, Paris, France, in 1983.

Sandrine Leonardi joins Diatos from ifrance (a VU group company) where she was Finance Director of the French company and its Spanish subsidiary (iespana). Ms. Leonardi’s prior positions include being Finance Controller Europe of Louis Vuitton Malletier and Head of Financial Control for Europe 2 Communication. Ms. Leonardi graduated from HEC, a leading French Business School, Paris, France, in 1992, and obtained a Masters in Political Science from Columbia University, New-York, USA, in 1993.

"We are pleased to have executives with Denis’s and Sandrine’s experience join our fast-growing company," said Dr John Tchelingerian, President and CEO of Diatos. "Denis’s experience in pharmaceutical development will be extremely valuable as we advance our pipeline of therapeutic products through preclinical and clinical development."

Contacts: Diatos
Dr. John Tchelingerian, President and CEO
Tel: +33 1 53 80 93 81

About Diatos
Diatos is a privately held biopharmaceutical company that uses its proprietary drug-targeting and intracellular-delivery technologies to develop innovative therapies for cancer and other serious diseases. Diatos has two core technology platforms:

Diatos Peptide Vector (DPV) technology enables or significantly enhances selective cellular or nuclear uptake of a broad range of therapeutic compounds, including small molecules, peptides and proteins, antibodies and antibody fragments, oligonucleotides, and nanospheres.

Tumor Selective Prodrug (TSP) technology enables the release of anti-cancer agents selectively at the sites of tumor cells.

In addition to using these technologies to develop its own product pipeline, Diatos is offering these technologies to pharmaceutical and biotechnology companies, under licensing or partnering relationships, for the development of a broad range of therapeutic products in various therapeutic fields and for target validation and drug screening.

Founded in 1999 as a spin-off from Institut Pasteur, Diatos has raised to date 23.5 Million Euros. Diatos has a total of 40 employees at its headquarters in Paris, France, and at the campus of Louvain-la-Neuve Université in Louvain, Belgium.


Over 40 CEOs from Europe and the US came together on the island of Corsica for a trans-Atlantic meeting of the minds

We’re pleased to announce that we recently held our inaugural Sofinnova CEO Conference, which we co-hosted with Sofinnova Ventures of San Francisco from March 20-22. Our goal was to provide our CEOs with constructive and thought-provoking workshops, as well as the opportunity to network with an international peer group. The conference brought unique trans-Atlantic value to our portfolio companies.

The event was a real success. Despite the coinciding outbreak of war, 43 CEOs from Europe and the US flew to Corsica to attend the 2-day event. Special guests who addressed the group included information technology keynote Jean-Francois Pontal, CEO of European telecommunications giant Orange SA; life science keynote Jean-Pierre Garnier, CEO of GlaxoSmithKline; Ken Alwyn, a senior partner in PricewaterhouseCoopers’ global organization; and Marco Landi, former president of BMC Europe, former COO of Apple Computer and former president of Texas Instruments Europe.

The CEOs discussed their business challenges and shared best practices regarding critical business issues such as surviving in an adverse economic environment, development of a global strategy, strategic business plan development, optimal sales force management, development of a customer-focused organization, corporate governance, and, of course, “managing your board.”
We will host CEO conferences annually, alternating the locale between Europe and the U.S.


esmertec and Insignia collaborate to deliver Over-the-Air Repair™ capabilities for mobile terminals

Zurich, Switzerland, February 11, 2003 * * *
esmertec AG, the leading global supplier of embedded Java? virtual machines (JVMs) for the mobile world, and Insignia Solutions today announced an agreement whereby esmertec acquires the Insignia JVM related assets with the exception of Jeode Intellectual Property. esmertec will assume the entire JVM business through a final asset purchase in June 2004. esmertec and Insignia will also work together to proliferate Insignia’s Secure System Provisioning technology to esmertec’s customers and markets. Insignia Solutions is a market-share leading supplier of JVM software solutions for high-growth markets including mobile, digital TV, telematics and embedded systems and has partnerships with many key industry players. This acquisition strengthens and consolidates esmertec’s leadership position in providing Java solutions for mass market mobile and embedded devices. Combining the esmertec and Insignia customer bases as well as best-in-class compiling technologies provides the mobile industry with a best-of-breed solution.

” This acquisition makes perfect sense from a number of perspectives”, said Alain Blancquart, CEO of esmertec. “The combined R&D team will be the largest and most experienced in the industry, allowing us to continue to deliver world-class solutions to our partners and customers”. “In addition to this we will be able to extend esmertec’s market reach by building on the strong position that Insignia has in the PDA, industrial and automotive markets. I am truly delighted by this deal and am excited about the future”, he concluded. Commenting on the complimentary compiling technologies of the two companies, Hansruedi Heeb, esmertec’s President and CTO, said: “We are excited by the prospect of combining the brainpower of the two leading engineering teams in compiling J2ME CLDC solutions and we look forward to strengthening our leadership in the entire embedded Java space thanks to Insignia’s outstanding and proven technology”. With the sale of Insignia’s JVM business to esmertec, Insignia is refocusing on its highly successful Secure System Provisioning product line. The two companies have agreed to work together to deliver an end-to-end Over-the-Air Repair solution leveraging the complimentary strengths of the two companies. In addition, Insignia will gain a highly leverage entry into esmertec’s customer base and markets with this solution. “We are delighted to have reached an agreement with esmertec”, said Mark McMillan, President and COO of Insignia. “This acquisition makes esmertec the leading worldwide provider of mobile services enabling software in the industry and the infusion of cash to Insignia enables us to exclusively focus on the significant market opportunity for Secure System Provisioning – it’s a win-win situation for both companies”.

About esmertec
esmertec is the leading software company focusing on Java™ and mobile software technologies for handheld systems. Considered to be one of the most important players in the independent VM supplier space, its flagship product, Jbed™ ME, certified by Sun Microsystems, delivers high performance computing on small devices to service providers, mobile device manufacturers and application developers. Founded in 1999, esmertec is based in Switzerland with sales, engineering and support offices in the United States and Singapore and representation in Japan.

About Insignia Solutions
Insignia Solutions’ provisioning-infrastructure software enables wireless carriers and mobile device manufacturers to fully capitalize on the mobile service opportunity. Founded in 1986, Insignia is a market-share leading supplier of Java virtual machine software solutions for high-growth markets including mobile, digital TV, telematics, and embedded systems. More than 40 million units of Insignia’s JVM™ technology are licensed by major partners including Samsung, HP/Compaq, BSQUARE, Wind River, Fujitsu, NEC, Toshiba, Motorola and Siemens AG. Insignia Solutions is traded on NASDAQ under the symbol INSG. The company is headquartered in Fremont, California with R&D and European operations based in the United Kingdom, and its Asian HQ in Japan. For additional information about Insignia or its products please visit http://www.insignia.com/.

Visit website http://www.esmertec.com


Paris, 13 December 2002. Sofinnova Partners announces the departure of Franck Delorme, General Partner responsible for developing the Information Technology sector alongside Olivier Protard. This move will not change the firm’s investment strategy, which is to focus on two key sectors: Information Technology and Life Sciences. The hiring of Alain Rodermann, Partner, in 1999 and the additions to the IT team over the last two years of a new Partner, Jean Schmitt, and two new Investment Associates, gives Sofinnova Partners the means to continue developing this sector.

” After twelve years of operational and international management experience with Dassault Systèmes, I joined Sofinnova Partners as General Partner in 1995. I have been with the firm for eight years, which corresponds to two investment cycles in this business. I now want to capitalize on these two types of experience, and focus on operational management with a strong entrepreneurial outlook”, said Franck Delorme.

Olivier Protard added: “This is a natural career move for Franck and we wish him well. Furthermore, while this decision was motivated by personal projects, it was a mutual agreement, within the partnership spirit that guides the entire team”.

During his eight years with Sofinnova Partners, Franck Delorme made twelve investments in both software and networking/telecom companies. Examples are Activia Networks, MaxiMiles, Ortems, Sefas, Solsoft, Staff & Line and, more recently, CTS and 6Wind.

About Sofinnova Partners
Based in Paris since 1972, Sofinnova Partners is a leading independent French and European venture capital firm. With key operations in the information technology and life science sectors, its investment strategy is based on two principles: “Invest in projects with a high potential in their early stages of development” and “Act as lead or co-lead investor”. Its investment team comprises 13 investment partners who are all experts in their field and can assist companies in which Sofinnova chooses to invest. Sofinnova Partners has more than 500 million euros under management, a loyal base of international investors, and plans to strongly reinforce its European development in the coming years.